Recent News

• 04.03.2025 - BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
• 03.31.2025 - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Recent Filings

• 04.01.2025 - 144 Report of proposed sale of securities
• 03.27.2025 - PRE 14A Other preliminary proxy statements
• 03.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.10.2025 - 144/A Report of proposed sale of securities
• 03.10.2025 - 144 Report of proposed sale of securities